Bold Therapeutics' Clinical-Stage Anticancer Agent BOLD-100 Demonstrates Neuroprotective Potential when Utilized in Combination with FOLFOX for the Treatment of Advanced Gastrointestinal Cancers
PRNewsWire
·
2026-05-28
·
via The Tech Buzz - Press Releases
VANCOUVER, BC, May 28, 2026 /PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company fou…
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。